phosphorothiolate oligodeoxyribonucleotide
Nucleic acidexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2004 (NCT00251394)
Timeline
Indications
Mechanism of action
- Intercellular adhesion molecule-1ANTISENSE INHIBITOR
ICAM1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- phosphorothiolate oligodeoxyribonucleotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00435812 | Phase 3 | Dec 1, 2006 | Dynavax Technologies Corporation |
| NCT00251394 | Phase 2 | Jul 1, 2004 | Dynavax Technologies Corporation, Harvard University, New York University, University of Rochester |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dynavax Technologies Corporation | For profit | 2 | 1 | 2 | 2004 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2004 |
4 organizations
Page 1 / 1